The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Molecularly Tailored Therapy for Pancreas Cancer
Official Title: A Pilot Study of Molecularly Tailored Therapy for Patients With Metastatic Pancreatic Cancer
Study ID: NCT01888978
Brief Summary: Patient therapy is tailored according to the molecular profile of the patient's tumor.
Detailed Description: This study is for patients with metastatic pancreatic cancer (cancer that has spread to other parts of the body). The purpose of this study is to determine whether molecularly tailored therapy can improve the effectiveness of standard chemotherapy combinations for patients with metastatic pancreatic cancer. A series of special tests will be performed on a sample of tumor, and based on the results subjects will be assigned to one of seven chemotherapy treatments, with each being the combination of two standard chemotherapies. Each of these combinations has been safely used in patients with pancreatic or other types of cancer. The purpose of this study is to to determine the ability to personalize therapy in this manner, and to determine how many patients a larger study would need. A second purpose is not to determine if one doublet is better than another. Rather, this second purpose is to show that for all patients enrolled in this protocol who have been assigned a doublet based on their tumor's molecular analysis (molecular tailoring), treatment response will be better than would be expected compared to patients who have been treated in the past with no molecular tailoring.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Georgetown University- Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States
MedStar Montgomery Medical Center, Olney, Maryland, United States
Name: Michael Pishvaian, MD
Affiliation: Georgetown University
Role: PRINCIPAL_INVESTIGATOR